Japan's Teijin Pharma and Sato Pharmaceutical will begin marketing Bonalfa lotion (tacalcitol), an ethical agent for treating psoriasis vulgaris, the companies announced.
Bonalfa is a new formulation of Bonalfa ointment, which is currently co-promoted by the two companies. Tacalcitol, which was initially discovered by Teijin, is activated vitamin D3.
Indicated for the treatment of keratosis, Tacalcitol is available for sale in approximately 30 countries worldwide. The two companies aim to generate a combined total of $7 million in sales per year by 2008.